Type of security: Stock
Sector: Capital Goods
The data is delayed by 15 minutes.
Description: Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devi
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||1%||Sales Growth - Q/Q||-7.34%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.59%||ROE||5.84%||ROI||3.02%|
|Current Ratio||4.12||Quick Ratio||2.28||Long Term Debt/Equity||1.55||Debt Ratio||0.18|
|Gross Margin||62.28%||Operating Margin||7.77%||Net Profit Margin||4.24%||Dividend Payout Ratio|
|Cash From Financing Activities||30.45 M||Cash From Investing Activities||-18.74 M||Cash From Operating Activities||49.74 M||Gross Profit||157.54 M|
|Net Profit||5 M||Operating Profit||13.95 M||Total Assets||1.64 B||Total Current Assets||608.25 M|
|Total Current Liabilities||155.75 M||Total Debt||654.14 M||Total Liabilities||926.17 M||Total Revenue||244.08 M|
|High 52 week||67.23||Low 52 week||46.55||Last close||46.57||Last change||-2.45%|
|RSI||15.2||Average true range||1.68||Beta||0.65||Volume||390.34 K|
|Simple moving average 20 days||-8.72%||Simple moving average 50 days||-15.96%||Simple moving average 200 days||-22.19%|
|Performance Week||-6.49%||Performance Month||-14.2%||Performance Quart||-26.04%||Performance Half||-30.16%|
|Performance Year||-6.8%||Performance Year-to-date||-2.7%||Volatility daily||1.66%||Volatility weekly||3.72%|
|Volatility monthly||7.62%||Volatility yearly||26.39%||Relative Volume||322.8%||Average Volume||562.8 K|
|New High||New Low|
2019-03-23 09:30:01 | Why Is Integra IART Down 0.5% Since Last Earnings Report?
2019-03-15 11:01:03 | Integra's Duragen Secures Japanese Nod to Drive Global Growth
2019-03-15 07:32:27 | Have Insiders Been Selling Integra LifeSciences Holdings Corporation NASDAQ:IART Shares?
2019-03-14 08:00:00 | Integra LifeSciences Announces the Approval of DuraGen® in Japan
2019-03-11 07:03:57 | Integra gets FDA warning letter for Boston plant
2019-03-11 06:33:46 | Integra gets FDA warning letter for Boston plant
2019-03-07 16:05:00 | Integra LifeSciences to participate in Healthcare Conference in March 2019
2019-02-28 09:47:02 | Integra Rides on Channel Expansion Strategy, New Alliances
2019-02-26 08:33:01 | Integra's IART Q4 Earnings and Revenues Beat Estimates
2019-02-24 09:16:05 | Is Integra LifeSciences Holdings Corporation NASDAQ:IART A Financially Sound Company?
2019-02-21 20:20:32 | Edited Transcript of IART earnings conference call or presentation 21-Feb-19 1:30pm GMT
2019-02-21 16:14:02 | Integra Lifesciences Holdings Corp IART Q4 2018 Earnings Conference Call Transcript
2019-02-21 10:45:03 | Integra LifeSciences IART Q4 Earnings and Revenues Top Estimates
2019-02-21 06:17:35 | Integra: 4Q Earnings Snapshot
2019-02-13 08:00:00 | Integra LifeSciences Launches the Integra® Panta® 2 TTC Arthrodesis Nail System
2019-01-11 09:39:02 | Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
2019-01-10 07:25:00 | Recent Analysis Shows T-Mobile US, Thor Industries, Integra LifeSciences, Diplomat Pharmacy, Tile Shop Hldgs, and Compass Diversified Market Influences — Renewed Outlook, Key Drivers of Growth
2019-01-10 06:30:00 | Integra LifeSciences Launches Integra® Titan™ Reverse Shoulder System-S
2019-01-09 09:15:02 | Integra IART Rises 5% on Robust Preliminary Q4 Results
2019-01-09 09:07:46 | Should We Worry About Integra LifeSciences Holdings Corporation’s NASDAQ:IART P/E Ratio?
2019-01-09 07:00:00 | Integra LifeSciences Appoints Rhonda Germany Ballintyn as Director
2019-01-08 07:00:00 | Integra LifeSciences Announces Preliminary Fourth Quarter 2018 Financial Results
2018-12-24 09:22:02 | Integra Rides on Global Prospects, Hurt by Escalating Costs
2018-12-22 03:49:29 | Do Hedge Funds Love Integra Lifesciences Holdings Corp IART?
2018-12-18 16:01:00 | Integra LifeSciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-12 12:13:00 | How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
2018-11-30 09:31:02 | Integra IART Down 2.2% Since Last Earnings Report: Can It Rebound?
2018-11-28 10:02:03 | Integra's IART Margin Pressure Hurts, Global Prospects High
2018-11-08 16:01:00 | Integra LifeSciences to participate in Healthcare Conferences in November 2018
2018-11-07 08:15:00 | Detailed Research: Economic Perspectives on Integra LifeSciences, American Assets Trust, Teekay Offshore Partners, Acacia Communications, Piedmont Office Realty Trust, and Macerich — What Drives Growth in Today's Competitive Landscape
2018-11-01 12:20:04 | Integra IART Q3 Earnings Meet Estimates, Revenue View Dips
2018-10-31 16:38:47 | Edited Transcript of IART earnings conference call or presentation 31-Oct-18 12:30pm GMT
2018-10-31 07:30:11 | Integra LifeSciences IART Matches Q3 Earnings Estimates